SARS-CoV-2 Quality Control for Molecular and Serology assays

Presented at: A Bio-Rad Quality Control Virtual Conference

Sponsored by: Bio-Rad Laboratories

Speakers

Duane W. Newton, PhD, D(ABMM), FIDSA

Director, Clinical Microbiology Laboratory, Associate Director, Division of Clinical Pathology, Professor of Pathology, University of Michigan
BIOGRAPHY
Elitza S. Theel, PhD, D(ABMM)

Director, Infectious Diseases Serology Laboratory, Clinical Microbiology Division, Department of Laboratory Medicine and Pathology, the Mayo Clinic, Minnesota
BIOGRAPHY

Abstract

SARS-CoV-2 has created significant challenges for laboratories, requiring the development, validation, and scale up of testing in a very short time period--often this was done for multiple methods due to capacity demands and supply chain shortages. Part of assuring quality test results is the confidence in testing that comes from a robust QC Program. In this webinar, the speakers will discuss different issues to be considered for QC material selection, as well as QC program design & strategies for SARS-CoV-2 molecular and serology testing.

Learning Objectives:

1. Describe approaches to quality control for SARS-CoV-2 molecular testing that monitor the entire testing process

2. Discuss quality control approaches for high-throughput SARS-CoV-2 antibody tests

3. List 2 optimal QC practices for each methodology

Resources:

SARS-CoV-2 Quality Control for Molecular and Serology Assays Handout

Q&A Sessions SARS-CoV-2 Quality Control for Molecular and Serology Assays